JP2005532389A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532389A5
JP2005532389A5 JP2004519100A JP2004519100A JP2005532389A5 JP 2005532389 A5 JP2005532389 A5 JP 2005532389A5 JP 2004519100 A JP2004519100 A JP 2004519100A JP 2004519100 A JP2004519100 A JP 2004519100A JP 2005532389 A5 JP2005532389 A5 JP 2005532389A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclic
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004519100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532389A (ja
JP4503436B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/002941 external-priority patent/WO2004005229A1/en
Publication of JP2005532389A publication Critical patent/JP2005532389A/ja
Publication of JP2005532389A5 publication Critical patent/JP2005532389A5/ja
Application granted granted Critical
Publication of JP4503436B2 publication Critical patent/JP4503436B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004519100A 2002-07-08 2003-06-25 糖質コルチコイド受容体のモジュレーター Expired - Fee Related JP4503436B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39442502P 2002-07-08 2002-07-08
PCT/IB2003/002941 WO2004005229A1 (en) 2002-07-08 2003-06-25 Modulators of the glucocorticoid receptor

Publications (3)

Publication Number Publication Date
JP2005532389A JP2005532389A (ja) 2005-10-27
JP2005532389A5 true JP2005532389A5 (OSRAM) 2006-08-17
JP4503436B2 JP4503436B2 (ja) 2010-07-14

Family

ID=30115721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519100A Expired - Fee Related JP4503436B2 (ja) 2002-07-08 2003-06-25 糖質コルチコイド受容体のモジュレーター

Country Status (20)

Country Link
US (2) US7138406B2 (OSRAM)
EP (1) EP1521733B1 (OSRAM)
JP (1) JP4503436B2 (OSRAM)
AR (1) AR041186A1 (OSRAM)
AU (1) AU2003281355A1 (OSRAM)
BR (1) BR0312575A (OSRAM)
CA (1) CA2491994C (OSRAM)
DK (1) DK1521733T3 (OSRAM)
ES (1) ES2518940T3 (OSRAM)
GT (1) GT200300138A (OSRAM)
HN (1) HN2003000207A (OSRAM)
MX (1) MXPA05000345A (OSRAM)
MY (1) MY135333A (OSRAM)
PA (1) PA8576901A1 (OSRAM)
PE (1) PE20040650A1 (OSRAM)
PT (1) PT1521733E (OSRAM)
SI (1) SI1521733T1 (OSRAM)
TW (2) TWI340738B (OSRAM)
UY (1) UY27884A1 (OSRAM)
WO (1) WO2004005229A1 (OSRAM)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2619608C (en) * 2005-08-18 2016-02-02 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR101335873B1 (ko) * 2006-03-21 2013-12-02 타민코 나암로제 베누트샤프 사료 요구율의 감소 또는 복수 발생률의 감소를 위한 가금류의 치료 방법
AR060536A1 (es) 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009542704A (ja) * 2006-07-07 2009-12-03 ボーシュ アンド ローム インコーポレイティド ドライ・アイを治療するための医薬組成物と方法
PT2051710E (pt) * 2006-08-07 2012-02-08 Bausch & Lomb Composições e métodos para tratar, reduzir, melhorar ou aliviar doenças oftálmicas do segmento posterior
PL2049112T3 (pl) * 2006-08-07 2012-07-31 Bausch & Lomb Leczenie infekcji i ich następstw za pomocą połączonych zdysocjowanych agonistów receptora glukokortykoidowego i środków przeciwzapalnych
SI2056799T1 (sl) * 2006-08-31 2013-11-29 Bausch & Lomb Incorporated Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
DE602007014067D1 (de) * 2006-09-11 2011-06-01 Bausch & Lomb Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
EA016494B1 (ru) 2007-02-02 2012-05-30 Пфайзер Продактс Инк. (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
US20080318915A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched fluticasone propionate
JP5265144B2 (ja) * 2007-06-27 2013-08-14 富山県 ３−ｏ−置換−カテキン類誘導体の新規製造方法
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2009105723A2 (en) * 2008-02-22 2009-08-27 Accelalox, Inc. Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2010013158A1 (en) 2008-07-28 2010-02-04 Pfizer Inc. Phenanthrenone compounds, compositions and methods
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
TWI516487B (zh) 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
IN2012DN01453A (OSRAM) 2009-08-20 2015-06-05 Novartis Ag
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
EP3007697B1 (en) 2013-06-14 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP6517318B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2020190351A1 (en) 2019-03-18 2020-09-24 Nieman Lynnette K Method for improving insulin sensitivity
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN116194114A (zh) 2020-03-26 2023-05-30 葛兰素史密斯克莱知识产权发展有限公司 用于防止或治疗病毒感染的组织蛋白酶抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010804B1 (en) * 1999-04-30 2006-05-31 Pfizer Products Inc. Glucocorticoid receptor modulators
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
JP2002193911A (ja) * 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター

Similar Documents

Publication Publication Date Title
JP2005532389A5 (OSRAM)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2008514732A5 (OSRAM)
JP2009537550A5 (OSRAM)
US11040035B2 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
JP2001515071A5 (OSRAM)
DK2510946T3 (en) Conjugates of synthetic fluorescent agonists and their applications
JP2018517746A5 (OSRAM)
JPWO2019147662A5 (OSRAM)
RU2013130256A (ru) Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
JP2018529671A5 (OSRAM)
JP2010504346A5 (OSRAM)
JP2012528161A5 (OSRAM)
JP2006506443A5 (OSRAM)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2009542716A5 (OSRAM)
JP2014513110A5 (OSRAM)
JP2008535902A5 (OSRAM)
JP2007535496A5 (OSRAM)
JP2010530881A5 (OSRAM)
JP2014500265A5 (OSRAM)
JP2013541514A5 (OSRAM)
JP2017519025A5 (OSRAM)